Stephen Krieger
Overview
Explore the profile of Stephen Krieger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keegan B, Absinta M, Cohen-Adad J, Flanagan E, Henry R, Klawiter E, et al.
Brain Commun
. 2024 Nov;
6(6):fcae395.
PMID: 39611182
Spinal cord disease is important in most people with multiple sclerosis, but assessment remains less emphasized in patient care, basic and clinical research and therapeutic trials. The North American Imaging...
2.
Sanky C, Gentile C, Ren J, Bortnick E, Krieger S
Neurol Educ
. 2024 Oct;
2(1):e200044.
PMID: 39411107
Background And Objectives: As resident physicians specialize, they lose familiarity with knowledge central to other fields. This can yield what we term the dual fallacies: (1) the sense that their...
3.
Krieger S, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Srinivasan J, et al.
J Neuroimmunol
. 2024 Jul;
393:578397.
PMID: 38959783
Objective: Evaluate the real-world effect of dimethyl fumarate (DMF) on subclinical biomarkers in patients with relapsing-remitting multiple sclerosis (RRMS) and compare with results from clinical trials. Methods: Magnetic resonance imaging...
4.
Krieger S, Cook K, Hersh C
Curr Opin Neurol
. 2024 Mar;
37(3):189-201.
PMID: 38535979
Purpose Of Review: Research in multiple sclerosis (MS) has long been predicated on clinical groupings that do not reflect the underlying biologic heterogeneity apparent within patient populations. This review explicates...
5.
Aboseif A, Roos I, Krieger S, Kalincik T, Hersh C
Neurol Clin
. 2023 Nov;
42(1):203-227.
PMID: 37980116
Randomized controlled trials (RCTs) are essential for regulatory approval of disease-modifying therapies (DMTs), yet their strict selection criteria often lead to limited generalizability. Observational studies using real-world data (RWD) allow...
6.
Barnett M, Wang D, Beadnall H, Bischof A, Brunacci D, Butzkueven H, et al.
NPJ Digit Med
. 2023 Oct;
6(1):196.
PMID: 37857813
Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical relapses, no magnetic resonance imaging (MRI) disease activity and no disability worsening. While MRI is the principal...
7.
8.
Satyanarayan S, Cutter G, Krieger S, Cofield S, Wolinsky J, Lublin F
Mult Scler
. 2023 Apr;
29(4-5):568-575.
PMID: 37119208
Background: Definitions of trial measures are consequential to accurately capturing outcomes and cross-trial comparability, particularly for derivative measures. Objective: Using CombiRx, examine the impact of relapse definition on endpoints and...
9.
Sand I, Gnjatic S, Krammer F, Tuballes K, Carreno J, Satyanarayan S, et al.
Mult Scler Relat Disord
. 2023 Jan;
70:104486.
PMID: 36628884
Background: People living with multiple sclerosis (MS) and other disorders treated with immunomodulatory therapies remain concerned about suboptimal responses to coronavirus disease 2019 (COVID-19) vaccines. Important questions persist regarding immunological...
10.
Zhang Y, Cofield S, Cutter G, Krieger S, Wolinsky J, Lublin F
Neurol Clin Pract
. 2022 Nov;
12(4):e58-e65.
PMID: 36382118
Background And Objectives: Disease activity in multiple sclerosis (MS) is highly variable, and there are limited prospective studies on predictors of disease outcomes. The goal of this study is to...